{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:48:20Z","timestamp":1790966900479,"version":"4.1.0"},"reference-count":35,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"abstract":"<jats:p>OBJECTIVE. Our aim was to describe the morbidity, medical costs, and nonmedical costs associated with group A streptococcal pharyngitis in school-aged children.<\/jats:p><jats:p>METHODS. Our study population included parents of children diagnosed as having group A streptococcal pharyngitis at 2 pediatric practice sites in the Boston, Massachusetts, metropolitan area. Telephone interviews were conducted with parents of eligible children, who were asked questions about health care utilization, medications, and time missed from work or school, for calculation of medical and nonmedical costs associated with illness.<\/jats:p><jats:p>RESULTS. One hundred thirty-five parents completed interviews between October 2005 and January 2006. Older children were significantly more likely to present with headache, compared with those \u22645 years of age. No significant differences between older and younger children were found for rates of sore throat, fever, abdominal pain\/nausea\/vomiting, or rash. Children missed a mean of 1.9 days (range: 0\u20137 days) of school\/day care, and 42% of parents missed a mean of 1.8 days of work. A second parent or caregiver also missed a mean of 1.5 days in 14% of families. The total societal cost per case of group A streptococcal pharyngitis was $205 (medical: $118; nonmedical: $87).<\/jats:p><jats:p>CONCLUSIONS. The societal cost of group A streptococcal pharyngitis is substantial, with almost one half being attributable to nonmedical costs. Through extrapolation from this experience, the total cost of group A streptococcal pharyngitis among children in the United States ranges from $224 to $539 million per year.<\/jats:p>","DOI":"10.1542\/peds.2007-0484","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T18:40:00Z","timestamp":1201891200000},"page":"229-234","source":"Crossref","is-referenced-by-count":133,"title":["Burden and Economic Cost of Group A Streptococcal Pharyngitis"],"prefix":"10.1542","volume":"121","author":[{"given":"Elizabeth","family":"Pfoh","sequence":"first","affiliation":[{"name":"Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Wessels","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Children's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Goldmann","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Children's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts"},{"name":"Division of Infectious Diseases, Children's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,2,1]]},"reference":[{"key":"2021120820174803800_R1","doi-asserted-by":"crossref","unstructured":"Linder JA, Bates DW, Lee GM, Finkelstein JA. Antibiotic treatment of children with sore throat. JAMA.\u20082005;294(18):2315\u20132322","DOI":"10.1001\/jama.294.18.2315"},{"key":"2021120820174803800_R2","doi-asserted-by":"crossref","unstructured":"Bisno AL. Acute pharyngitis: etiology and diagnosis. Pediatrics.\u20081996;97(6):949\u2013954","DOI":"10.1542\/peds.97.6.949"},{"key":"2021120820174803800_R3","doi-asserted-by":"crossref","unstructured":"O'Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995\u20131999. Clin Infect Dis.\u20082002;35(3):268\u2013276","DOI":"10.1086\/341409"},{"key":"2021120820174803800_R4","doi-asserted-by":"crossref","unstructured":"Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: a retrospective population-based study. JAMA.\u20081993;269(3):384\u2013389","DOI":"10.1001\/jama.269.3.384"},{"key":"2021120820174803800_R5","doi-asserted-by":"crossref","unstructured":"Haukness HA, Tanz RR, Thomson RB Jr, et al. The heterogeneity of endemic community pediatric group A streptococcal pharyngeal isolates and their relationship to invasive isolates. J Infect Dis.\u20082002;185(7):915\u2013920","DOI":"10.1086\/339407"},{"key":"2021120820174803800_R6","doi-asserted-by":"crossref","unstructured":"Muotiala A, Seppala H, Huovinen P, Vuopio-Varkila J. Molecular comparison of group A streptococci of T1M1 serotype from invasive and noninvasive infections in Finland. J Infect Dis.\u20081997;175(2):392\u2013399","DOI":"10.1093\/infdis\/175.2.392"},{"key":"2021120820174803800_R7","doi-asserted-by":"crossref","unstructured":"Cockerill FR III, MacDonald KL, Thompson RL, et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA.\u20081997;277(1):38\u201343","DOI":"10.1001\/jama.277.1.38"},{"key":"2021120820174803800_R8","doi-asserted-by":"crossref","unstructured":"McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis.\u20082005;41(8):1114\u20131122","DOI":"10.1086\/444458"},{"key":"2021120820174803800_R9","doi-asserted-by":"crossref","unstructured":"Haber M, Barskey A, Baughman W, et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine.\u20082007;25(29):5390\u20135398","DOI":"10.1016\/j.vaccine.2007.04.088"},{"key":"2021120820174803800_R10","doi-asserted-by":"crossref","unstructured":"Kotloff KL, Fattom A, Basham L, et al. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase 1 trial. JAMA.\u20082004;292(6):709\u2013715","DOI":"10.1001\/jama.292.6.709"},{"key":"2021120820174803800_R11","doi-asserted-by":"crossref","unstructured":"Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis.\u20082004;39(11):1572\u20131580","DOI":"10.1086\/425006"},{"key":"2021120820174803800_R12","unstructured":"US Department of Health and Human Services. Medicare Program: Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B: Final Rule. Washington, DC: US Department of Health and Human Services; 2005. Report 42, CFR part 405:70458"},{"key":"2021120820174803800_R13","unstructured":"American Academy of Pediatrics. Massachusetts Medicaid Reimbursement AAP 2004\/05 Report. Elk Grove Village, IL: American Academy of Pediatrics; 2005. Available at: www.aap.org\/research\/medreimpdf0405\/ma.pdf. Accessed March 15, 2006"},{"key":"2021120820174803800_R14","unstructured":"Fleming T, ed. 2005 Drug Topics Red Book. Montvale, NJ: Thomson Medical Economics; 2005"},{"key":"2021120820174803800_R15","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2021120820174803800_R16","unstructured":"US Census Bureau. Annual Demographic Survey: March Supplement PINC-01 Selected money characteristics or people 15 years and over by total money income in 2004, work experience in 2004, race, Hispanic origin, and sex. [Female]. Washington, DC: US Census Bureau; 2005. Available at: http:\/\/pubdb3.census.gov\/macro\/032005\/perinc\/new01_046.html. Accessed March 15, 2006"},{"key":"2021120820174803800_R17","unstructured":"US Census Bureau. Annual Demographic Survey: March Supplement PINC-01 Selected money characteristics or people 15 years and over by total money income in 2004, work experience in 2004, race, Hispanic origin, and sex. [Male]. Washington, DC: US Census Bureau; 2005. Available at: http:\/\/pubdb3.census.gov\/macro\/032005\/perinc\/new01_037.html. Accessed March 15, 2006"},{"key":"2021120820174803800_R18","unstructured":"US House of Representatives, Committee on Ways and Means. Section 9, child care, Table 9\u201319. In: Green Book 2003. Washington, DC: US House of Representatives, Committee on Ways and Means; 2003. Available at: http:\/\/waysandmeans.house.gov\/media\/pdf\/greenbook2003\/Section9.pdf. Accessed July 9, 2007"},{"key":"2021120820174803800_R19","unstructured":"Bureau of Labor Statistics. Consumer Price Index for Food and Energy: Boston-Brockton-Nashua, MA-NH-ME-CT. Washington, DC: Bureau of Labor Statistics; 2005. USDL-06-008"},{"key":"2021120820174803800_R20","unstructured":"Energy Information Administration. Annual Energy Outlook\u20082006: With Projections to 2030. Washington, DC: Energy Information Administration; 2006. Available at: www.scag.ca.gov\/rcp\/pdf\/publications\/1_2006AnnualEnergyOutlook.pdf. Accessed March 15, 2006"},{"key":"2021120820174803800_R21","unstructured":"Internal Revenue Service. IRS announces 2006 standard mileage rates. Available at: www.irs.gov\/newsroom\/article\/0,id=151226,0.html. Accessed March 15, 2006"},{"key":"2021120820174803800_R22","unstructured":"National Aeronautics and Space Administration. Gross domestic product deflator inflation calculator. Available at: www1.jsc.nasa.gov\/bu2\/inflateGDP.html. Accessed March 2, 2006"},{"key":"2021120820174803800_R23","doi-asserted-by":"crossref","unstructured":"Widdowson M, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics.\u20082007;119(4):684\u2013697","DOI":"10.1542\/peds.2006-2876"},{"key":"2021120820174803800_R24","doi-asserted-by":"crossref","unstructured":"Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA.\u20081994;271(5):375\u2013381","DOI":"10.1001\/jama.271.5.375"},{"key":"2021120820174803800_R25","doi-asserted-by":"crossref","unstructured":"Capra AM, Lieu TA, Black SB, Shinefield HR, Martin KE, Klein JO. Costs of otitis media in a managed care population. Pediatr Infect Dis J.\u20082000;19(4):354\u2013355","DOI":"10.1097\/00006454-200004000-00019"},{"key":"2021120820174803800_R26","doi-asserted-by":"crossref","unstructured":"Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non\u2013influenza-related viral respiratory tract infection in the United States. Arch Intern Med.\u20082003;163(4):487\u2013494","DOI":"10.1001\/archinte.163.4.487"},{"key":"2021120820174803800_R27","doi-asserted-by":"crossref","unstructured":"Schoen C, Davis K, How SK, Schoenbaum SC. US health system performance: a national scorecard. Health Aff (Millwood).\u20082006;25(6):w457\u2013w475","DOI":"10.1377\/hlthaff.25.w457"},{"key":"2021120820174803800_R28","unstructured":"Dingle JH, Badger GF, Jordan WS. Streptococcal infection. In: Dingle JH, Badger GF, Jordan WS, eds. Illness in the Home. Cleveland, OH: Western Reserve University; 1964:97\u2013117"},{"key":"2021120820174803800_R29","doi-asserted-by":"crossref","unstructured":"Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med.\u20082002;346(16):1200\u20131206","DOI":"10.1056\/NEJMoa013169"},{"key":"2021120820174803800_R30","doi-asserted-by":"crossref","unstructured":"Cohen R, Levy C, de La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J.\u20082006;25(11):1001\u20131007","DOI":"10.1097\/01.inf.0000243163.85163.a8"},{"key":"2021120820174803800_R31","doi-asserted-by":"crossref","unstructured":"O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine.\u20082003;21(17\u201318):1815\u20131825","DOI":"10.1016\/S0264-410X(02)00807-1"},{"key":"2021120820174803800_R32","unstructured":"Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease: United States, 1998\u20132003. MMWR Morb Mortal Wkly Rep.\u20082005;54(36):893\u2013897"},{"key":"2021120820174803800_R33","doi-asserted-by":"crossref","unstructured":"Tan TQ. Pneumococcal conjugate vaccines: implications for community antibiotic prescribing. Curr Opin Microbiol.\u20082000;3(5):502\u2013507","DOI":"10.1016\/S1369-5274(00)00130-2"},{"key":"2021120820174803800_R34","doi-asserted-by":"crossref","unstructured":"Seppa\u0308la\u0308 H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland: Finnish Study Group for Antimicrobial Resistance. N Engl J Med.\u20081997;337(7):441\u2013446","DOI":"10.1056\/NEJM199708143370701"},{"key":"2021120820174803800_R35","doi-asserted-by":"crossref","unstructured":"Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis.\u20082004;10(3):514\u2013517","DOI":"10.3201\/eid1003.030252"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/2\/229\/1122092\/zpe00208000229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/2\/229\/1122092\/zpe00208000229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T21:55:01Z","timestamp":1708552501000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/2\/229\/68725\/Burden-and-Economic-Cost-of-Group-A-Streptococcal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,2,1]]},"published-print":{"date-parts":[[2008,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-0484","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}